Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Combination of viral and bacterial antigens
Reexamination Certificate
2008-07-29
2008-07-29
Duffy, Patricia A. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Combination of viral and bacterial antigens
C424S226100, C424S258100, C424S682000, C424S690000, C424S698000, C424S093600
Reexamination Certificate
active
10485748
ABSTRACT:
A vaccine composition comprising two valences is provided: (i) a first valence which is adjuvant-enhanced with aluminum hydroxide and (ii) a second valence which contains a polysaccharide of bacterial capsule comprising one or more o-acetyl groups and which is not adsorbed with aluminum oxide due to the presence of a protecting compound which may be a phosphate, a citrate or a carbonate and which prevents the adsorption. The first valence can be any vaccine valence. In one particular embodiment, the vaccine composition contains (i) Hepatitis A valence, adsorbed on aluminum hydroxide and (ii) the typhoid fever valence formed by the polysaccharide Vi of theSalmonella typhicapsule.
REFERENCES:
patent: 6585973 (2003-07-01), Lees
patent: WO 96 37222 (1996-11-01), None
patent: WO 9637222 (1996-11-01), None
patent: WO 99 48525 (1999-09-01), None
patent: WO 0012129 (2000-03-01), None
patent: 00/12129 (2000-09-01), None
patent: WO 0062801 (2000-10-01), None
Havrix Monodose (Hepatitis A) Vaccine Patienti Information Leaflet. Available from GlaxoSmithKiline/SmithKline Beecham.
Van Hoecke et al. 1998 J Travel Med 5:116-120.
Adju-phos product monograph.
Beran et al. 2000. J. Travel Med 7:246-252.
Stroop. Feb. 2002 Carbohydrate Research 337:335-344.
Strugess et al. 1999. Vaccine 17:1169-1178.
Rinella et al. 1995. Journal of Colloid and Interface Science vol. 172 p. 121-130.
Havrix product monograph 2001.
Corbel, M.J. “Reasons for Instability of Bacterial Vaccines”,Dev. Biol. Stand., vol. 87, pp. 133-124. (1996).
Dumas, R., et al., “Safety And Immunogenicity Of A New Inactivated Hepatitis A Vaccine In Concurrent Administration With A Typhoid Fever Vaccine Or A Typhoid Fever + Yellow Fever Vaccine”Advances in Therapy, vol. 14, No. 4, pp. 160-167 (Jul./Aug. 1997).
Van Hoecke, C. et al., “Concomitant Vaccination against Hepatitis A and Typhoid Fever”J. Travel. Med. vol. 5, pp. 116-120 (1998).
Translation of PCT International Preliminary Examination Report, International Application No. PCT/FR2002/002770, International Filing Date: Jul. 31, 2002.
Aventis Pasteur SA
Duffy Patricia A.
Ogunbiyi Oluwatosin
LandOfFree
Multivalent vaccine composition having increased stability... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent vaccine composition having increased stability..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent vaccine composition having increased stability... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3952764